EvolveImmune United, Inc
EvolveImmune Therapeutics is an innovative immuno-oncology company focused on developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency in solid tumors and hematological cancers. The company is advancing a pipeline of novel T cell engager platforms, notably EVOLVE104, which targets tumor antigens with integrated CD2 co-stimulation, aiming to improve treatment outcomes and address unmet medical needs in oncology.
Industries
Nr. of Employees
small (1-50)
EvolveImmune United, Inc
23 Business Park Drive, Branford, CT 06405
Products
ULBP2-targeted multispecific T cell engager (lead clinical candidate)
A multispecific T cell engager designed to conditionally target ULBP2-family antigens on squamous-lineage and select solid tumors while providing integrated CD2 costimulation to enhance T cell activity and durability.
CD20-targeted 2:1 bispecific T cell engager with CD2 costimulation
A 2:1-format CD20-targeted multispecific engager designed for B cell malignancies and autoimmune indications that pairs tumor targeting with CD2 costimulatory engagement to improve potency and tolerability.
B7-H4-targeted T cell engager program for ER-low and TNBC
A multispecific T cell engager engineered to target B7-H4-expressing breast tumors (estrogen receptor-low and triple-negative subtypes) with integrated CD2 costimulation and potential for combination with other therapies.
ULBP2-targeted multispecific T cell engager (lead clinical candidate)
A multispecific T cell engager designed to conditionally target ULBP2-family antigens on squamous-lineage and select solid tumors while providing integrated CD2 costimulation to enhance T cell activity and durability.
CD20-targeted 2:1 bispecific T cell engager with CD2 costimulation
A 2:1-format CD20-targeted multispecific engager designed for B cell malignancies and autoimmune indications that pairs tumor targeting with CD2 costimulatory engagement to improve potency and tolerability.
B7-H4-targeted T cell engager program for ER-low and TNBC
A multispecific T cell engager engineered to target B7-H4-expressing breast tumors (estrogen receptor-low and triple-negative subtypes) with integrated CD2 costimulation and potential for combination with other therapies.
Services
Collaborative translational studies with clinical and academic partners to characterize tumor antigen expression, immune infiltration and inform clinical patient selection.
Chemistry, manufacturing and control activities to enable biologics scale-up, clinical supply chain planning, and CDMO coordination for first-in-human studies.
Preclinical efficacy, safety, PK and toxicology study execution including comparative benchmarking, cytokine release evaluation, and non-clinical model testing to support IND-enabling packages.
Collaborative translational studies with clinical and academic partners to characterize tumor antigen expression, immune infiltration and inform clinical patient selection.
Chemistry, manufacturing and control activities to enable biologics scale-up, clinical supply chain planning, and CDMO coordination for first-in-human studies.
Preclinical efficacy, safety, PK and toxicology study execution including comparative benchmarking, cytokine release evaluation, and non-clinical model testing to support IND-enabling packages.
Expertise Areas
- Immuno-oncology drug discovery
- Multispecific antibody engineering
- Preclinical pharmacology and safety assessment
- Translational biomarker development and patient selection
Key Technologies
- CRISPR-Cas9 in vivo screening
- Multispecific (trispecific/bispecific) antibody engineering
- 2:1 bispecific antibody formats
- Supported lipid bilayer immunological synapse assays
News & Updates
EvolveImmune Therapeutics has announced a collaboration with Memorial Sloan Kettering Cancer Center to investigate the expression of ULBP2 in muscle-invasive bladder cancer, leveraging MSK’s translational medicine capabilities to inform the development of EVOLVE104.
An article discussing the emerging trend of using dual T cell engaging bispecific antibodies to enhance tumor activation, highlighting the potential of costimulatory strategies such as those developed by EvolveImmune.
Stephen Bloch, MD, was named the 2023 BioCT Entrepreneur of the Year for his leadership and innovation in Connecticut's bioscience industry.
EvolveImmune Therapeutics has announced a collaboration with Memorial Sloan Kettering Cancer Center to investigate the expression of ULBP2 in muscle-invasive bladder cancer, leveraging MSK’s translational medicine capabilities to inform the development of EVOLVE104.
An article discussing the emerging trend of using dual T cell engaging bispecific antibodies to enhance tumor activation, highlighting the potential of costimulatory strategies such as those developed by EvolveImmune.
Stephen Bloch, MD, was named the 2023 BioCT Entrepreneur of the Year for his leadership and innovation in Connecticut's bioscience industry.